Entecavir may cause musculoskeletal problems.

user321

This drug may also cause the following symptoms that are related to musculoskeletal problems:

• Muscle pain/soreness  肌肉疼痛
  
• Muscle weakness        肌肉无力
  
  

Musculoskeletal side effects also included arthralgia(关节痛) and myalgia（肌病).

Metabolic

Metabolic side effects have included elevated lipase (greater than or equal to 2.1 times ULN; 7%), fasting hyperglycemia (greater than 250 mg/dL; up to 3%), elevated alkaline phosphatase, and elevated amylase. Decreased blood bicarbonate has been reported in 2% of entecavir-treated patients with hepatic decompensation. Lactic acidosis has been reported during postmarketing experience.

Genitourinary

Genitourinary side effects have included hematuria (Grade 3 to 4; 9%), glycosuria (Grade 3 to 4; 4%), and dysuria.

Renal

Renal side effects have included confirmed creatinine increases of 0.5 mg/dL or more (up to 2%). A confirmed increase in serum creatinine of 0.5 mg/dL (11%) and renal failure (less than 1%) have been reported in entecavir-treated patients with hepatic decompensation.

Respiratory

Respiratory side effects have included upper respiratory tract infection, cough, nasopharyngitis, and rhinitis. Upper respiratory infection has been reported in 10% of entecavir-treated patients with hepatic decompensation.

Gastrointestinal

Gastrointestinal side effects of moderate to severe intensity (Grade 2 to 4) have included diarrhea (up to 1%), dyspepsia (up to 1%), nausea (less than 1%), and vomiting (less than 1%). Abdominal pain (unspecified) and upper abdominal pain have also been reported. Deaths due to gastrointestinal hemorrhage were reported in entecavir-treated patients with hepatic decompensation.

Oncologic

Oncologic side effects have included malignant neoplasms occurring at a rate of 8.4 per 1000 patient-years. Hepatocellular carcinoma has been reported in 6% of entecavir-treated patients with hepatic decompensation.

Nervous system

Nervous system side effects of moderate to severe intensity (Grade 2 to 4) have included headache (up to 4%), dizziness (less than 1%), and somnolence (less than 1%).

Hematologic

Hematologic side effects have included decreased albumin (less than 2.5 g/dL) and platelets (less than 50,000/mm3) in less than 1% of patients.

Immunologic

Immunologic side effects have included anaphylactoid reaction during postmarketing experience.

Psychiatric

Psychiatric side effects of moderate to severe intensity (Grade 2 to 4) have included insomnia (less than 1%).

Dermatologic

Dermatologic side effects have included erythema. Rash and alopecia have been reported during postmarketing experience.

Hypersensitivity

Hypersensitivity side effects have included photosensitivity with lethargy in at least one patient, which resolved after stopping entecavir.

user321

看来化药也不靠谱，痛哭流涕啊

ainile

强烈建议中文！实在的不懂！

lin12345

这种药物也可能会导致肌肉骨骼有关系的问题以下症状：

肌肉疼痛/酸痛，肌肉疼痛
肌肉无力，肌肉无力


肌肉骨骼的副作用还包括关节痛（关节痛）和肌痛（肌病）。

代谢

代谢副作用包括脂肪酶升高（大于或等于正常值上限的2.1倍，7％），空腹血糖（大于250毫克/升，高达3％），碱性磷酸酶升高，升高淀粉酶。降低血液中的碳酸氢根报道2肝失代偿恩替卡韦治疗的患者％。乳酸性酸中毒有报道在上市后的经验。
泌尿生殖系

泌尿生殖系统的副作用包括血尿（3至4级，9％），尿糖（3至4级，4％），及排尿困难。
肾

肾脏的副作用包括确认为0.5毫克/升以上（高达2％），肌酐增加。以血清肌酐确认增加0.5毫克/升（11​​％）和肾功能衰竭（少于1％）已被报告与肝失代偿恩替卡韦治疗的患者。
呼吸

呼吸系统的副作用包括上呼吸道感染，咳嗽，鼻咽炎，和鼻炎。上呼吸道感染已报告10例肝失代偿恩替卡韦治疗的患者％。
胃肠道

中度至重度强度（2至4级），已包括腹泻（高达1％），消化不良（高达1％），恶心（少于1％），呕吐（少于1％），胃肠道副作用。腹部疼痛（未指明），上腹部疼痛也有报道。由于消化道出血死亡的报道在肝失代偿恩替卡韦治疗的患者。
肿瘤学

肿瘤学的副作用包括在1000年的8.4每病人年间发生的恶性肿瘤。肝癌已报告6例肝失代偿恩替卡韦治疗的患者％。
神经系统

神经系统强度的中度至重度副作用（2至4级），已包括头痛（达4％），头晕（少于1％），和嗜睡（少于1％）。
血液

血液的副作用包括降低白蛋白（小于2.5克/升）和血小板（小于50,000 /立方毫米），在不到1％的患者。
免疫

免疫副作用包括过敏性反应期间上市的经验。
精神科

中度至重度强度精神病的副作用（2至4级），已包括失眠（小于1％）。
皮肤科

皮肤病的副作用包括红斑。皮疹和脱发在上市后已报告的经验。
过敏症

过敏症的副作用包括至少在一个病人，这解决了与恩替卡韦停药后昏睡光敏性。